• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance

    "3 Key Trends" with Rafael Costa

    Schreiner MediPharm Introduces Tailored Tamper-Proof Closure Seals

    FDA Watch: Is Your Supply Chain at Risk?
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene International Ltd.

    Quotient Sciences

    TaiMed Biologics

    Almac Group

    U.S. Pharmacopeia (USP)
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene International Ltd.

    Quotient Sciences

    TaiMed Biologics

    Almac Group

    U.S. Pharmacopeia (USP)
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Advanced Analytics Advancing Development of Genetic Vaccines

    Leveraging innovative advanced analytical technologies to ensure regulatory compliance in the development and production of novel vaccines.

    Advanced Analytics Advancing Development of Genetic Vaccines
    Kristin Brooks, Managing Editor, Contract Pharma03.29.21
    The pandemic has prompted drug developers and regulators to develop and approve new medicines and vaccines in record time. Importantly, it’s not just traditional medicines using established technologies and processes but new drug modalities, such as RNA therapeutics, reaching clinical trials within two years of development. So, how has this been possible? One of the key factors facilitating these unprecedented development timelines has been leveraging innovative advanced analytical technologies to ensure regulatory compliance in the development and production of these novel vaccines.

    Dr. Susan Darling, Ph.D., Senior Director of Biopharma Market and Product Management within the Global Biopharma and CE Business Unit at SCIEX, shares insight into what’s fueling the growth of new drug modalities, key factors facilitating rapid development timelines, and the role of advanced analytical technologies. –KB

    Contract Pharma: What is fueling the growth and rapid advancement of new drug modalities?

    Susan Darling: Pre-COVID demands for more rapid, accurate, and automated methods was growing. An evolution towards semi- or fully continuous and flexible processes was already happening, but it was going at a slow pace, which is common in pharma, an industry averse to change. COVID hit the fast forward button, making the need for speed a necessity for vaccine development. The results that have been achieved have shown that timelines can safely and effectively be optimized using next generation methods. 
     
    Traditional vaccines are based on weakened or attenuated viruses that stimulate the production of antibodies that bind to the virus in question and prevent it from invading host cells. While they provide good immune responses, it generally takes many years to develop and commercialize them. More modern vaccines are derived from recombinant simulants of the relevant disease antigen in special forms that enable effective delivery, such as virus-like particles. These approaches, which have included new vaccines for Ebola and Dengue, have shorter development times (1–2 vs 4–5 years).
     
    Newer genetic vaccines take a different approach to production and eliminate the need to work with live viruses. Approaches including those based on naked (plasmid) DNA, viral vectors, and messenger RNA (mRNA) cause the production of viral proteins inside cells, using native protein translation and post-translational modification machinery within the cells.
     
    DNA and mRNA vaccines are typically delivered in the form of a lipid nanoparticle that enters human cells, which then produce the antigens that generate the desired immune response. With viral-vector vaccines, the engineered virus delivers the nucleic acid encoding the viral antigen to the cells.
     
    CP: What are the key factors facilitating rapid development timelines?
     
    SD: Once the genetic sequence of the infectious agent has been identified, genetic vaccines can be rapidly designed and processes for their expression developed and scaled for clinical and commercial production. No cell bank or viral seed bank must be developed, and genetic vaccines require much lower doses. Production therefore can be achieved in a smaller footprint employing single use technologies, and scale up is typically quicker than for traditional viral vaccines.
     
    Importantly, unlike with attenuated and subunit vaccines that require development of a new process for each vaccine, with these genetic technologies only creation of the genetic sequence for the parts of the virus being targeted is required to generate a new vaccine. The formulation, production, packaging and even the safety profiles are nearly identical across different vaccines. The ability to use robust, scalable platform processes that are nearly identical from one vaccine product to the next greatly reduces development timelines.
     
    CP: What role do advanced analytical technologies play in drug development?
     
    SD: Access to robust and scalable analytical processes for DNA, viral vector and mRNA vaccines is a challenge today given the short turnaround time for obtaining analytical results. The functional cell-based assays and infectivity studies that have been used for traditional vaccine development can take days to weeks to generate results. The decision to progress a batch must often be made within 24 hours or less, however; manufacturers must use limited information for the decision to move ahead with a process and thus risk losing time and costly product.
     
    The development of consistent, scalable, rapid functional analytical methods is critical for improving the manufacturing of genetic vaccines. Without speedy assays, the ability to fully understand all the relevant process parameters and how they impact product quality attributes is limited, which prevents the development of robust processes.
     
    Advances in automation and data analysis have the potential to reduce analysis times as well as simplify analyses while increasing consistency and accuracy. These assays must also have greater sensitivity and precision given the often-low production volumes for genetic vaccines.
     
    CP: How is this different from more traditional drug development methods?
     
    SD: To overcome the challenges associated with the development of robust analytical solutions for genetic vaccines, many analytical technologies initially developed for protein therapeutics have been modified to address the assessment needs for genetic vaccines. Experience is also being drawn from the gene therapy field. Other methods have been developed to meet the unique analysis needs presented by these novel technologies.
     
    Instrument manufacturers and software developers are committed to both modifying existing methods and developing new techniques that simplify and reduce the time required for analysis of novel modalities.
     
    The goal is to provide high-throughput, robust platform methods with high specificity, precision and resolution for the detection and quantification of biologic compounds, even in the most complex and challenging samples so that novel medicines such as genetic vaccines can be safely brought to market as rapidly as possible.
     
    CP: How is advanced analytical technology being leveraged to ensure regulatory compliance in development and production?
     
    SD: New robust assays based on mass spectrometry (MS) and capillary electrophoresis combined with laser-induced fluorescence (CE-LIF) and other detection methods rapidly provide accurate and reproducible results for both the protein and genetic components of DNA and viral-vector vaccines (plasmid isoform, recombinant DNA sequencing, etc.) Liquid chromatography-MS/MS methods are valuable for sequence confirmation and rapid and reproducible detection, separation and sizing of mRNA, high-resolution analysis of important 5’ cap and 3’ poly-A tail fragments and confirmation of LNP composition.

    Acoustic Ejection Mass Spectrometry (AEMS) eliminates tedious sample preparation, time-consuming liquid chromatography method development and chromatographic run times while providing access to the compound tuning and specificity of MS at the high-throughput speeds associated with plate readers.

    Similarly, the direct coupling of capillary Isoelectric Focusing (cIEF) charge variant analysis with high-resolution MS enables rapid analysis of intact viral vector capsid proteins, allowing users to make more informed and timely decisions when they are needed.

    All these methods contribute to the acceleration of critical decision-making and in turn reduction of developmenttimelines and costs, both of which are essential for successful drug development today.
     

    Susan Darling is the Sr. Director of Biopharma Market and Product Management within the Global Biopharma and CE Business Unit at SCIEX. She is responsible for driving growth in the Biopharma segment, development and execution of strategic direction, as well as new product and workflow development.
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss
    Bora Pharmaceuticals Bora Pharmaceuticals
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Boyds Opens US Office in PA Boyds Opens US Office in PA
    GeneQuine, Exothera Enter Gene Therapy Partnership GeneQuine, Exothera Enter Gene Therapy Partnership
    Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration
    Repligen and Navigo Launch Antibody Technology Platform Repligen and Navigo Launch Antibody Technology Platform
    GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy

    Related Breaking News

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
      Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss

      Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss

      Novel AAV capsid Anc80 enables efficient gene transfer.
      02.01.23

    • Bora Pharmaceuticals

      Bora Pharmaceuticals

      ...
      Lonnie Barish, VP, Business Development 03.09.22

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21


    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Tania Moorehead, Global Marketing Manager 10.20.21

    • Breaking News | Clinical Trials
      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      According to the study, the novel prophylactic nasal spray prevented infection from SARS-CoV-2, the virus that causes COVID-19.
      09.22.21

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Contract Pharma
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Societal CDMO Partners With Atossa Therapeutics
    • Videobite: Contract Pharma Sits Down with Ryan Lake of Societal CDMO
    Breaking News
    • Catalent Adds New Cryogenic Capabilities at Japanese Facility
    • Lifecore Biomedical Enters into $150M New Financing Deal
    • WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    • Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    • GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Launches Cost-Cutting Program and Organizational Realignment in Germany
    BASF Strengthens R&D with More Powerful Supercomputer
    Safic-Alcan Expands its Presence in Africa with the Launch of Safic-Alcan East Africa in Kenya
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
    Remote Monitoring, Digital Health Help Advance Wound Care Treatment
    MLM Biologics Developing Wound Infection Prevention Device for Military
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Catalent Adds New Cryogenic Capabilities at Japanese Facility
    Lifecore Biomedical Enters into $150M New Financing Deal
    WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Robots & Artificial Intelligence are Transforming Unilever's Material Innovation Factory
    Top 10 Most Popular Hair Care Brands in the U.S.—Ranked by Searches
    Aloette Cosmetics Launches Daily Mineral Shield Sunscreen
    Happi

    Latest Breaking News From Happi

    Revieve Launches Beauty Technology Platform on Google Cloud Marketplace
    BBW’s Fabric Softener Launch, Ameon’s New Ambassador
    Mielle Organics Taps Angel Reese as New Ambassador
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX Digital, Mexar and hubergroup Top This Week’s Stories
    Richnerstutz AG Acquires an EFI VUTEk Q5r Superwide Roll-to-Roll Printer
    BASF Strengthens Its R&D with More Powerful Supercomputer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mactac acquires Label Supply, Beontag grows and more
    Sun Chemical releases Spring 2023 Regulatory Newsletter
    Tageos unveils new RAIN RFID inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Corman, Tosama Develop Biodegradable Plastic Tampon Applicator, Trevira Changes Name
    Suominen Appoints SVP, Transformation Management Office
    Minnesota Signs PFAS Ban in Consumer Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AlloSource Launches AlloMend Duo Acellular Dermal Matrix
    TendoNova Inks Partnership With AcCELLerated Biologics
    Stryker Achieves First Surgeries Using Q Guidance System with Cranial Guidance Software
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Smart Skis, Universal Display Top This Week’s Stories
    Wiliot Appoints Antony Yousefian as VP of Climate & Circularity
    HID Unveils Eco-friendly Bamboo Access Cards

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login